RudaCure Inc., a 风投企业 specializing in the development of treatments for 感觉障碍, announced on the 30th that its self-developed 干眼症治疗药 候选物质 RCI001 has been recognized for its commercialization potential and has been selected for the 产业通商资源部's '研发 Rediscovery Project,' the 中小企业部' '2020 BIG3 Sector SME Innovation Growth Support Project,' and 仁川科技园's '初创企业 Park Project,' thereby laying the foundation for 临床试验.
https://www.donga.com/news/It/article/all/20200729/102213491/2